THE PCCA BLOG
US$ 21.24
dpp4 and glp 1 combination Table 2 from DPP- 4 Inhibitors in the Management of Type 2 Diabetes Mellitus Dipeptidyl peptidase-4 inhibitor - Wikipedia
Description
Do not recap the syringe needle
A qualified clinician should review benefits, risks, contraindications, and long-term treatment needs
For some patients, weight regain despite intensive lifestyle efforts may warrant consideration of resuming tirzepatide or transitioning to alternative anti-obesity medications, provided they meet FDA-indicated criteria (BMI 30 kg/m or 27 kg/m with weight-related comorbidity)
This can be OK for some people who may respond well and not need a more potent drug, or those with less body fat to lose
